CA3162227A1 - Composes antiviraux, compositions et procedes d'utilisation - Google Patents

Composes antiviraux, compositions et procedes d'utilisation Download PDF

Info

Publication number
CA3162227A1
CA3162227A1 CA3162227A CA3162227A CA3162227A1 CA 3162227 A1 CA3162227 A1 CA 3162227A1 CA 3162227 A CA3162227 A CA 3162227A CA 3162227 A CA3162227 A CA 3162227A CA 3162227 A1 CA3162227 A1 CA 3162227A1
Authority
CA
Canada
Prior art keywords
alkyl
branched
carbon linear
ocf3
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3162227A
Other languages
English (en)
Inventor
David Scott Grierson
Maryam ZAMIRI
Peter K. Cheung
Benoit Chabot
Alan Walter COCHRANE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
University of Toronto
Societe de Commercialisation des Produits de la Recherche Appliquee SOCPRA
Original Assignee
University of British Columbia
University of Toronto
Societe de Commercialisation des Produits de la Recherche Appliquee SOCPRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, University of Toronto, Societe de Commercialisation des Produits de la Recherche Appliquee SOCPRA filed Critical University of British Columbia
Publication of CA3162227A1 publication Critical patent/CA3162227A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés antiviraux ayant la structure de formule (I) et des compositions de ceux-ci destinés à être utilisés dans le traitement d'une infection virale. En particulier, les composés de formule (I) sont capables d'interférer avec l'exportation de traitement d'ARNm viral tel que réfléchi dans l'accumulation modifiée d'isoformes d'ARN viral ainsi que le transport du noyau vers le cytoplasme. De tels composés présentent une réduction de l'infection par le VIH, l'adénovirus et le coronavirus des cellules. L'invention concerne des composés qui peuvent être appropriés pour le traitement du VIH/SIDA. (Formule (I))
CA3162227A 2019-12-16 2020-12-15 Composes antiviraux, compositions et procedes d'utilisation Pending CA3162227A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962948672P 2019-12-16 2019-12-16
US62/948,672 2019-12-16
PCT/CA2020/051724 WO2021119808A1 (fr) 2019-12-16 2020-12-15 Composés antiviraux, compositions et procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA3162227A1 true CA3162227A1 (fr) 2021-06-24

Family

ID=76476511

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3162227A Pending CA3162227A1 (fr) 2019-12-16 2020-12-15 Composes antiviraux, compositions et procedes d'utilisation

Country Status (6)

Country Link
US (1) US20230105935A1 (fr)
EP (1) EP4077320A4 (fr)
JP (1) JP2023506860A (fr)
CN (1) CN115151536A (fr)
CA (1) CA3162227A1 (fr)
WO (1) WO2021119808A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02012596A (es) * 2000-06-21 2003-04-10 Hoffmann La Roche Derivados de benzotiazol.
EP1680431A1 (fr) * 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Compositions de benzothiazole et de thiazole'5,5-b!pyridine et leur utilisation comme inhibiteurs de l'ubiquitine ligase
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2009012558A (es) * 2007-08-03 2010-04-21 Biomarin Iga Ltd Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.

Also Published As

Publication number Publication date
CN115151536A (zh) 2022-10-04
WO2021119808A1 (fr) 2021-06-24
US20230105935A1 (en) 2023-04-06
EP4077320A4 (fr) 2024-01-03
JP2023506860A (ja) 2023-02-20
EP4077320A1 (fr) 2022-10-26

Similar Documents

Publication Publication Date Title
CA2801848C (fr) Methode destinee a reguler la phosphorylation de la proteine sr, et agents antiviraux comprenant le regulateur de l'activite de la proteine sr comme principe actif
JP5361879B2 (ja) ブロモフェニル置換チアゾリルジヒドロピリミジン
ES2332434T3 (es) Derivados de quirolina como inhibidores de la integrasa del vih.
WO2015164956A1 (fr) Composés dérivés de benzisothiazole utilisés comme agents thérapeutiques et leurs méthodes d'utilisation
CA2874250A1 (fr) Derives d'acide 7-oxothiazolopyridine carbonique et leur utilisation dans le traitement, l'amelioration ou la prevention d'une maladie virale
RU2661895C2 (ru) Соединение сложного эфира гуанидинобензойной кислоты
JP4121151B2 (ja) 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物
Gawali et al. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted-2, 3-dihydro-1H-naphtho [1, 2-e][1, 3] oxazines as potent HIV-1 reverse transcriptase inhibitors
CN112920141B (zh) 一类大黄酸衍生物及其抗病毒用途
US8466177B2 (en) Treating and preventing viral infections
KR20090007609A (ko) ＲＮａｓｅ Ｌ을 활성화시키는 항-바이러스 제제
EP1796662A2 (fr) Inhibition des virus a l'aide d'inhibiteurs de rnase h
CA3162227A1 (fr) Composes antiviraux, compositions et procedes d'utilisation
WO2015171951A1 (fr) Composés 2-(4-aryl-1h-imidazol-1-yl)aniline
WO2019099426A1 (fr) Nucléoprotéine ciblant un inhibiteur du virus de la grippe
CN101759684A (zh) 二芳基嘧啶类衍生物及其制备方法和用途
Balzarini et al. Oxathiin carboxanilide derivatives: a class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs
CN102834381A (zh) 用于抑制hiv整合酶的吡哆辛衍生物
CN112724156A (zh) 一种多环吡啶酮衍生物和药物组合物及其应用
Mao et al. Structural modifications of diarylpyrimidine-quinolone hybrids as potent HIV-1 NNRTIs with an improved drug resistance profile
KR20010083056A (ko) 새로운 티올에스테르 및 그것의 이용
CA2881967C (fr) Inhibiteurs de la proteine phosphatase-1 et leurs utilisations
CN111303136B (zh) 6-(1,3-苯并二氧基-5-(甲)基)-取代尿嘧啶衍生物、合成方法、应用、药物
JP7061394B2 (ja) キノリノン化合物および抗ｒｎａウイルス薬
Vaickelioniene et al. Tumosien e, I.; Jonuškien e, I.; Mickevicius, V. Synthesis of Novel Aminothiazole Derivatives as Promising Antiviral, Antioxidant and Antibacterial Candidates